Clinical development of pomaglumetad methionil: A non-dopaminergic treatment for schizophrenia

Neuropharmacology

Volumn 66, Issue , 2013, Pages 82-86

  Kinon, Bruce J ^a   Gómez, Juan Carlos ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Glutamate; Metabotropic glutamate receptors (mGluR2), (mGluR3); Schizophrenia

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; PLACEBO; POMAGLUMETAD METHIONIL; RISPERIDONE;

AGITATION; AKATHISIA; ANXIETY DISORDER; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EOSINOPHILIA; EXTRAPYRAMIDAL SYNDROME; GENETIC MARKER; HUMAN; INSOMNIA; LOW DRUG DOSE; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; PERIODONTITIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT GAIN;

AMINO ACIDS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; EXCITATORY AMINO ACID AGONISTS; HUMANS; SCHIZOPHRENIA;

EID: 84872130954     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.06.002     Document Type: Review

References (25)

1. Adams, D.H.; Kinon, B.J.; Baygani, S.; et al.; Unpublished results, manuscript submitted 2011. A long-term, Phase 2, multicenter, randomized, open-label, comparative safety study of LY2140023 versus atypical antipsychotic standard of care in patients with DSM-IV-TR schizophrenia.
2. K. Alper, K.A. Schwartz, R.L. Kolts, and A. Khan Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports Biol. Psychiatry 62 4 2007 345 354
3. C.M. Beasley Jr.; T. Sanger, W. Satterlee, G. Tollefson, P. Tran, and S. Hamilton Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial Psychopharmacology (Berl) 124 1-2 1996 159 167
4. J.R. Bishop, V.L. Ellingrod, J. Moline, and D. Miller Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment Schizophr. Res. 77 2005 253 260
5. J.P. Conn, C.W. Lindsley, and C.K. Jones Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 30 1 2008 25 31
6. C. Corti, G. Battaglia, G. Molinaro, B. Riozzi, A. Pittaluga, M. Corsi, M. Mugnaini, F. Nicoletti, and V. Bruno The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection J. Neurosci. 27 2007 8297 8308
7. M.F. Egan, R.E. Straub, T.E. Goldberg, I. Yakub, J.H. Callicott, A.R. Hariri, V.S. Mattay, A. Bertolino, T.M. Hyde, C. Shannon-Weickert, M. Akil, J. Crook, R.K. Vakkalanka, R. Balkissoon, R.A. Gibbs, J.E. Kleinman, and D.R. Weinberger Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia Proc. Natl. Acad. Sci. U. S. A 101 2004 12604 12609
8. M.J. Fell, K.W. Perry, and J.F. Falcone In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-Aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-Oxa-4-Aminobicyclo[3.1.0] Hexane-4,6- dicarboxylic acid (LY379268) J. Pharmacol. Exp. Ther. 331 3 2009 1126 1136
9. M.J. Fell, K.A. Svensson, B.G. Johnson, and D.D. Schoepp Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4- Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039) J. Pharmacol. Exp. Ther. 326 2008 209 217
10. B.A. Fijal, B.J. Kinon, S. Kapur, V.L. Stauffer, R.R. Conley, H.H. Jamal, J.M. Kane, M.M. Witte, and J.P. Houston Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia Pharmacogenomics J. 9 2009 311 318
11. J. González-Maeso, R.L. Ang, and T. Yuen Identification of a serotonin/glutamate receptor complex implicated in psychosis Nature 452 7183 2008 93 97
12. B.J. Kinon, K.M. Dale, and D.L. McKinzie mGlu2/3 receptor agonists: a new treatment approach for schizophrenia Glutamate Neuropsychiatr. Dis. 8 2008 147 155
13. B.J. Kinon Clinical aspects of modulation of glutamateric mechanisms in the treatment of schizophrenia Drugs Fut 35 7 2010 557
14. B.J. Kinon, A.J. Potts, and S.B. Watson Placebo response in clinical trials with schizophrenia patients Curr. Opin. Psychiatr. 24 2 2011 107 113
15. B.J. Kinon, L. Zhang, B.A. Millen and the HBBI Study Group A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia J. Clin. Psychopharmacol. 31 3 2011 349 355
16. B.J. Kinon, D.H. Adams, S. Baygani, B.A. Millen, I. Velona, and S.A. Kollack-Walker Long-term, phase 2, safety study of LY2140023 monohydrate versus atypical antipsychotic standard of care in schizophrenia Schizophr Bull. 37 Suppl. 1 2011 311
17. [Lilly] Eli Lilly and Company, May 2011, Investigator's Brochure for LY2140023.
18. W. Liu, A.C. Downing, and L.M. Munsie Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia Pharmacogenomics J. 2010 Sep, pp. 1-9
19. C.H. Mallinckrodt, L. Zhang, W.R. Prucka, and B.A. Millen Signal detection and placebo response in schizophrenia: parallels with depression Psychopharmacol. Bull. 43 1 2010 53 72
20. G.J. Marek, R.A. Wright, D.D. Schoepp, J.A. Monn, and G.K. Aghajanian Physiological antagonism between 5-hydroxytryptamine (2A) and group II metabotropic glutamate receptors in prefrontal cortex J. Pharmacol. Exp. Ther. 292 1 2000 76 87
21. G.J. Marek, B. Behl, A.Y. Bespalov, G. Gross, Y. Lee, and H. Schoemaker Glutamatergic (N-methyl-D-Aspartate receptor) hypofrontality in schizophrenia: too little Juice or a miswired brain? Mol. Pharmacol. 77 3 2010 317 326
22. McKinzie, D.; Fell, M.; Knitowski, K.; Johnson, B.; Anderson, W.; Paulissen, P.; Perry, K.; Svensson, K.; Monn, J.; April 2011. Synergistic Interactions of the mGlu2/3 Receptor Agonist LY404039 with Antipsychotic Agents in Behavioral and Neurochemical Animal Models Predictive of Antipsychotic Efficacy. Presented at the International Congress on Schizophrenia Research, Colorado Springs, CO, USA.
23. F. Nicoletti, J. Bockaert, G.L. Collingridge, P.J. Conn, F. Ferraguti, D.D. Schoepp, J.T. Wroblewski, and J.P. Pin Metabotropic glutamate receptors: from the workbench to the bedside Neuropharmacology 60 2011 1017 1041
24. Nisenbaum, L.K.; Zhao, F.; Downing, A.; et al.; Confirmation of a Significant Association Between a Genetic Marker in HTR2A and Response to the mGlu2/3 Agonist LY2140023 Monohydrate in the Treatment of Schizophrenia. Poster presented at: European College of Neuropsychopharmacology (ECNP) Congress, 3-7 September 2011, Paris, France.
25. S.T. Patil, L. Zhang, and F. Martenyi Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nat. Med. 13 9 2007 1102 1107